Rapid removal of atherosclerotic plaque
Drug Development Technology - ETC-216 Phospholipid Therapy for Coronary Heart Disease (CHD) Patients: "CLINICAL TRIALS SUGGEST ETC-216 MAY REVERSE ATEHROSCLEROSIS
The phase II clinical trial that has attracted media interest was carried out in 57 patients with acute coronary syndrome (ACS), who were randomised to five-weekly infusions of either ETC-216, at one of two doses, or placebo (saline). Intravascular ultrasound (IVUS) was performed within two weeks of patients experiencing ACS (baseline) and after each weekly infusion. The primary outcome measure was the change from baseline in percentage atheroma volume, as measured by IVUS, in the combined ETC-216 cohort. Results showed that five weeks of treatment with ETC-216 produced a significant, 4.2% reduction in atheroma volume (p<0.01).
Trial investigators in the US have described the results of the phase II study as 'unprecedented' and the best example to date that directly targeting HDL offers therapeutic benefit in patients with CHD."
The phase II clinical trial that has attracted media interest was carried out in 57 patients with acute coronary syndrome (ACS), who were randomised to five-weekly infusions of either ETC-216, at one of two doses, or placebo (saline). Intravascular ultrasound (IVUS) was performed within two weeks of patients experiencing ACS (baseline) and after each weekly infusion. The primary outcome measure was the change from baseline in percentage atheroma volume, as measured by IVUS, in the combined ETC-216 cohort. Results showed that five weeks of treatment with ETC-216 produced a significant, 4.2% reduction in atheroma volume (p<0.01).
Trial investigators in the US have described the results of the phase II study as 'unprecedented' and the best example to date that directly targeting HDL offers therapeutic benefit in patients with CHD."
posted by Alistair | Wednesday, March 15, 2006
0 Comments:
Post a Comment
<< Home